

AVISO IMPORTANTE – El Curriculum Vitae no podrá exceder de 4 páginas. Para rellenar correctamente este documento, lea detenidamente las instrucciones disponibles en la web de la convocatoria.

IMPORTANT – The Curriculum Vitae cannot exceed 4 pages. Instructions to fill this document are available in the website.

CV Date 19/03/2025

Part A. DPERSONAL INFORMATION

First Name	Julio Juan		
Family Name	Gálvez Peralta		
Sex (*)		Date of Birth (dd/mm/yyyy)	
DNI, NIE, Passport			
Email Address	jgalvez@ugr.es	URL Web	http://farmacologiagranada.ugr.es/member/galvez-peralta-julio-juan/
Open Researcher and Contributor ID (ORCID) (*)	0000-0001-6876-3782		

* datos obligatorios

A.1. Current position

Job Title	Full Professor / Catedrático de Universidad		
Starting date	2010		
Institution	Universidad de Granada		
Department / Centre	Departamento de Farmacología / Facultad de Farmacia		
Country	Spain	Phone	(34) 958241793
Keywords	320903 - Evaluation of drugs; 320905 - Pharmacognosy; 320990 - Experimental Pharmacology		

A.2. Previous positions (Research Career breaks included)

Period	Job Title / Name of Employer / Country
1995 - 2010	Profesor Titular de Universidad / Universidad de Granada / Spain
1991 - 1995	Profesor Ayudante L.R.U. / Universidad de Granada / Spain
1987 - 1991	Contratado predoctoral (FPU) / Universidad de Granada / Spain

(Incorporar todas las filas que sean necesarias)

A.3. Education

Degree/Master/PhD	University/Country	Year
Doctor in Pharmacy PhD	University of Granada / Spain	1990
Bachelor in Pharmacy	University of Granada / Spain	1987

(Incorporar todas las filas que sean necesarias)

Parte B. CVA Summary

Bachelor of Pharmacy from the University of Granada (UGR) in 1986; Doctor of Pharmacy (UGR) in 1990 (cum laude and Doctorate Special Prize). Training Scholarship Research Staff of the Ministry of Education and Science (1987); Assistant Professor L.R.U. (1991); Associate Professor (1995); Full Professor (2010) in the Department of Pharmacology (UGR). Participation in teaching undergraduate and graduate since 1991. Supervisor of 27 Doctorate Thesis, all with the highest rating, eight of them with European and/or international mention.



Three stays at research centers: 1) Biologie und Laboratorium of Farmaceutische Phytopharmacologie (KU Leuven, Belgium), led by Prof. Joseph Lemli (1989); 2) Department of Pharmacology and Therapeutics, University of Malaga, led by Prof. Felipe Sanchez de la Cuesta (1993); 3) Centre for Adult & Paediatric Gastroenterology, Barts & the London School of Medicine & Dentistry at the University of London (UK), led by Prof. Ian R. Sanderson (2005). Member of the Research group "Pharmacology of Natural Products" at UGR (CTS-164), involved in the evaluation of active compounds on intestinal inflammatory conditions and metabolic syndrome, related to immune response and its impact on intestinal microbiota. Participation in 26 research projects with public funding (16 as main researcher) and 26 projects with private funding (19 as principal investigator). This activity is reflected in 168 manuscripts in the field of Pharmacology, Gastroenterology and Nutrition: 78 with the IF in the first quartile (30 in the first decile) and 3 patents. h-index: 54. Head of the Department of Pharmacology at the University of Granada. Member of CIBER-EHD (ISCIII) and the Institute of Biosanitary Research of Granada (ibs.GRANADA). NUMBER OF RESEARCH PERIODS: 6

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

1. Scientific paper. Xia Y; Wei X; Gao P; et al; Sun H; (10/17) Gálvez J. 2024. Bismuth-based drugs sensitize *Pseudomonas aeruginosa* to multiple antibiotics by disrupting iron homeostasis. *Nature Microbiology*. 9-10, pp.2600-2613. <https://doi.org/10.1038/s41564-024-01807-6>

2. Scientific paper. Hidalgo-Garcia L; Ruiz-Malagon AJ; Huertas F; et al; Anderson P; (11/13) Galvez J (AC). 2023. Administration of intestinal mesenchymal stromal cells reduces colitis-associated cancer in C57BL/6J mice modulating the immune response and gut dysbiosis. *Pharmacological Research*. 195, pp.106891. <https://doi.org/10.1016/j.phrs.2023.106891>. Number of cites: 4

3. Scientific paper. Díaz-Villamarín X; Fernández-Varón E; Rojas Romero MC; Callejas-Rubio JL; Cabeza-Barrera J; Rodriguez-Nogales A; (7/8) Galvez J; Moron R. 2023. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation. *Biomedicine and Pharmacotherapy*. 168, pp.115706. <https://doi.org/10.1016/j.biopha.2023.115706> Number of cites: 4

4. Scientific paper. Ruiz-Malagon AJ; Hidalgo-Garcia L; Rodriguez-Sojo MJ; et al; (16/16) Galvez J. 2023. Tigecycline reduces tumorigenesis in colorectal cancer via inhibition of cell proliferation and modulation of immune response. *Biomedicine and Pharmacotherapy*. 163, pp.114760. <https://doi.org/10.1016/j.biopha.2023.114760> Number of cites: 4

5. Scientific paper. Diez-Echave P; Vezza T; Algieri F; et al.; (15/15) Galvez J. 2022. The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome. *Biomedicine and Pharmacotherapy*. 153, pp. 113445. <https://doi.org/10.1016/j.biopha.2022.113445> Number of cites: 6

6. Scientific paper. Molina-Tijeras JA; Diez-Echave P; Vezza T; et al.; (15/15) Galvez J. 2021. *Lactobacillus fermentum* CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis. *Pharmacological Research*. 167. pp. 105471. <https://doi.org/10.1016/j.phrs.2021.105471> Number of cites: 53

7. Scientific paper. Diez-Echave P; Vezza T; Rodríguez-Nogales A; et al.; (18/18) Galvez J. 2020. The prebiotic properties of Hibiscus sabdariffa extract contribute to the beneficial effects in diet-induced obesity in mice. Food Research International.127. pp. 108722. doi: <https://doi.org/10.1016/j.foodres.2019.108722> Number of cites: 39

8. Scientific paper. Vezza T; Rodríguez-Nogales A; Algieri F; et al.; (17/17) Galvez J. 2019. The metabolic and vascular protective effects of olive (Olea europaea L.) leaf extract in diet-induced obesity in mice are related to the amelioration of gut microbiota dysbiosis and to its immunomodulatory properties. Pharmacological Research. 150. pp. 104487. <https://doi.org/10.1016/j.phrs.2019.104487> Number of cites: 55

9. Scientific paper. Garrido-Mesa J; Rodríguez-Nogales A; Algieri F; et al.; (12/12) Galvez J. 2018. Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution British Journal of Pharmacology. 175. pp. 4353-4370. <https://doi.org/10.1111/bph.14494> Number of cites: 37

10. Review. Ruiz-Malagón AJ, Rodríguez-Sojo MJ, Redondo E, Rodríguez-Cabezas ME, Gálvez J, Rodríguez-Nogales A. (5/6) 2024. Systematic review: The gut microbiota as a link between colorectal cancer and obesity. Obesity Reviews. 2024. Pp. 13872. <https://doi.org/10.1111/obr.13872>

C.2. Congress

C.3. Research projects

1 Project. PID2022-143102OB-I00, Desarrollo de nuevas estrategias terapéuticas en obesidad basadas en la comunicación microbioma-mitocondria. Proyectos de generación de conocimiento. Ministerio de Ciencia, Innovación y Universidades. Galvez J. (University of Granada). 01/10/2023- 30/09/2026. 137.500 €. Principal investigator.

2 Project. ERAPERMED2022-114, A multi-omic stratification and a non-invasive tool for early recognition of triple negative and Her2+ breast cancer patients responders to neoadjuvant therapy (PORTRAIT) (ERAPERMED2022-114). ERA PERMED 2022. Leon J. (ibs.GRANADA). 01/01/2023-01/01/2026. 1.325.076 €. Team member.

3 Project. B-CTS-664-UGR20. El microbioma como biomarcador predictivo de la eficacia del tratamiento farmacológico en pacientes con síndrome metabólico (MIFASIME). Junta de Andalucía. Galvez J. (University of Granada). 01/07/2021-30/06/2023. 30.000 €. Principal investigator.

4 Project. P18-RT-4930, Relationship of host MHC variations and gut microbiota as a determinant in the onset and clinical presentation of inflammatory bowel disease in Andalusia. P18-RT-4930. Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía. Gálvez J. (University of Granada). 01/03/2020-28/02/2023. 140.352 €. Principal investigator.

5 Project. PI19/01058, Microbiota asociada a la mucosa en obesidad: una diana terapéutica para el tratamiento y prevención del cáncer colorrectal. Instituto de Salud Carlos III. Galvez J. (University of Granada). 01/01/2020- 31/12/2022. 129.470 €. Principal investigator.

6 Project. CV20-77708, Análisis multi-ómico en pacientes con covid-19 como predictor de la evolución de la enfermedad y su respuesta al tratamiento. Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía. Julio Galvez. (University of Granada). 04/09/2020-03/09/2021. 75.000 €. Principal investigator.

7 Project. PIE16/00045, Implementation of a novel platform to monitor tumour heterogeneity as a crucial determinant for individualized diagnostic and therapeutic outcome. Instituto de

Salud Carlos III. Julio Galvez. (University of Granada). 01/01/2017 - 31/12/2019. 495.000 €. Co-Principal investigator.

8 Project. AGL2015-67995-C3-3-R, Nutracéuticos de 2ª generación de plantas comestibles basados en extractos polifenólicos moduladores del metabolismo energético: Aplicaciones en la prevención de la obesidad. Ministerio de Economía y Competitividad. Julio Galvez. (University of Granada). 01/01/2016 - 31/12/2018. 90.000 €. Principal investigator.

9 Project. P10-AGR-6826, Investigaciones dirigidas a la validación etnofarmacológica de plantas medicinales de la Comunidad Autónoma Andaluza con actividad antiinflamatoria y antitumoral. Junta Andalucía. Julio Galvez. (University of Granada). 06/07/2011 - 30/04/2016. 208.247 €. Principal investigator.

C.4. Participation in technology/knowledge transfer activities and exploitation of results

Include patents and other intellectual property activities (contracts, licenses, agreements, etc.) in which you have collaborated. Indicate: a) the order of signature of authors; b) reference; c) title; d) priority countries; e) date; f) entity and companies that exploit the patent or similar information, if applicable.

1 Contract. Intervention study focused on the intestinal microbiome to evaluate the impact of a Wild Thyme Extract (*Thymus serpyllum*) extract with anti-inflammatory and metabolic properties. Finzelberg GmbH & Co KG (Germany). Galvez J. (University of Granada). 01/04/2023-01/04/2024. 83.000 €. Principal investigator.

2 Patent. Nuevos metodos para la aplicación de un producto para la modulacion de la respuesta inmunológica en humanos. Inventores/autores/obtentores: Galvez J; Rodriguez-Cabezas ME; Baños A Entidad titular de derechos: DOMCA, S.A. (ABONOS NATURALES). N° de solicitud: WO2015128516. Fecha de registro: 03/09/2015

3 Patent. Probiotic strains having cholesterol absorbing capacity, mehods and uses thereof Inventores/autores/obtentores: Sañudo A; Criado R; Rodríguez-Nogales A; Garach A; Olivares M; Galvez J; de la Escalera S; Duarte J; Zarzuelo A; Bañuelos O Entidad titular de derechos: Biosearch S.A. N° de solicitud: EP14384202.9 Fecha de registro: 10/12/2014. Fecha de concesión: 10/02/2015

4 Patent. New caramels with high content in prebiotic oligosaccharides, their preparation and use. Inventores/autores/obtentores: E. M. Rubio Castillo; M. Gómez García; C. Ortiz Mellet; J. Manuel García Fernández; A. Zarzuelo Zurita; J. J. Gálvez Peralta; R. Duval. Entidad titular de derechos: CSIC-Universidad de Sevilla-Universidad de Granada-Chirosep N° de solicitud: ES/P200700675 País de inscripción: España. Fecha de registro: 01/01/2007